Initiation of a Fourth Proprietary Drug Discovery Programme
VASTox announces the initiation of a fourth proprietary drug discovery programme focused on the bone morphogenetic protein (BMP) signaling pathway.
Released 22nd November 2005

Interim Results for the Six Months Ended 31 July 2005
Released 12th October 2005

Sir Brian Richards CBE Joins VASTox Board
VASTox plc announces the appointment of Sir Brian Richards CBE to the Board of VASTox as a Non-Executive Director.
Released 7th October 2005

Initiation of a New Proprietary Programme
VASTox announces today that it has initiated a new drug discovery programme focused on the treatment of Spinal Muscular Atrophy (SMA), a genetic neuromuscular disease.
Released 21st July 2005

Two New Agreements
VASTox announces that it has signed two new agreements in the field of drug development services and chemical genomics.
Released 20th June 2005

Result of AGM
VASTox announces that all of the resolutions at the AGM of the Company, held today, were duly passed.
Released 3rd June 2005

Preliminary Results for the Year Ended 31 January 2005
VASTox plc (AIM: VOX), the drug discovery and chemical genomics company, today announces its audited preliminary results for the year ended 31 January 2005.
Released 3rd May 2005

VASTox Presents Progress on its Duchenne Muscular Dystrophy Programme
Professor Kay Davies FRS, CBE, presents a scientific breakthrough in new research, in the field of muscular dystrophy, to the Oxford Innovation Society.
Released 8th April 2005

Appointments to the Scientific Advisory Board (SAB)
VASTox appoints three new members to its Scientific Advisory Board. They include Professor Francesco Muntoni, Professor Roger Patient and Dr Marcel van den Heuvel.
Released 10th March 2005

VASTox Wins Drug Discovery Contract in another New Area of Technology
VASTox announces that it has signed a contract with an undisclosed European biotech company in the area of targeting of drugs to specific organs and cell types through the use of sugars.
Released 23rd February 2005

Deal with MNL Pharma - VASTox Screen Validates MNL's Compound Activity
VASTox announces a chemical genomics screening deal with MNLpharma (formerly Molecular Nature).
Released 31st January 2005